

Study: ENGOT-ov81 / RAMP 301

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

MaNGO Sites:

Prov.	City	Site	Principal Investigator	Active
BS	Brescia	Spedali Civili	Germana Tognon	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	

* **MaNGO Principal Investigator**